vs
FGI Industries Ltd.（FGI）与REGENXBIO Inc.（RGNX）财务数据对比。点击上方公司名可切换其他公司
FGI Industries Ltd.的季度营收约是REGENXBIO Inc.的1.0倍（$30.5M vs $30.3M），FGI Industries Ltd.净利率更高（-8.6% vs -221.3%，领先212.7%），REGENXBIO Inc.同比增速更快（43.0% vs -14.4%），FGI Industries Ltd.自由现金流更多（$2.3M vs $-52.8M），过去两年REGENXBIO Inc.的营收复合增速更高（39.4% vs -0.5%）
FGI Industries Ltd是一家全球厨卫产品、家居收纳解决方案及家装用品的设计、制造与分销商，服务覆盖北美、欧洲及亚太地区的大型连锁零售商、家居专营店和电商平台。
REGENXBIO Inc.是一家临床阶段生物技术企业，专注于开发针对罕见及严重遗传疾病的突破性基因疗法。公司拥有专有的腺相关病毒载体技术，既向全球生物制药合作伙伴提供技术授权，也自主推进多疾病领域的基因疗法管线研发。
FGI vs RGNX — 直观对比
营收规模更大
FGI
是对方的1.0倍
$30.3M
营收增速更快
RGNX
高出57.4%
-14.4%
净利率更高
FGI
高出212.7%
-221.3%
自由现金流更多
FGI
多$55.1M
$-52.8M
两年增速更快
RGNX
近两年复合增速
-0.5%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $30.5M | $30.3M |
| 净利润 | $-2.6M | $-67.1M |
| 毛利率 | 26.7% | — |
| 营业利润率 | -2.2% | -190.0% |
| 净利率 | -8.6% | -221.3% |
| 营收同比 | -14.4% | 43.0% |
| 净利润同比 | -553.1% | -31.2% |
| 每股收益（稀释后） | $-1.63 | $-1.30 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收FGIRGNX
| Q4 25 | $30.5M | $30.3M | ||
| Q3 25 | $35.8M | $29.7M | ||
| Q2 25 | $31.0M | $21.4M | ||
| Q1 25 | $33.2M | $89.0M | ||
| Q4 24 | $35.6M | $21.2M | ||
| Q3 24 | $36.1M | $24.2M | ||
| Q2 24 | $29.4M | $22.3M | ||
| Q1 24 | $30.8M | $15.6M |
净利润FGIRGNX
| Q4 25 | $-2.6M | $-67.1M | ||
| Q3 25 | $-1.7M | $-61.9M | ||
| Q2 25 | $-1.2M | $-70.9M | ||
| Q1 25 | $-629.1K | $6.1M | ||
| Q4 24 | $-402.3K | $-51.2M | ||
| Q3 24 | $-550.1K | $-59.6M | ||
| Q2 24 | $163.6K | $-53.0M | ||
| Q1 24 | $-412.2K | $-63.3M |
毛利率FGIRGNX
| Q4 25 | 26.7% | — | ||
| Q3 25 | 26.5% | — | ||
| Q2 25 | 28.1% | — | ||
| Q1 25 | 26.8% | — | ||
| Q4 24 | 24.6% | 70.2% | ||
| Q3 24 | 25.8% | 48.8% | ||
| Q2 24 | 30.5% | 52.5% | ||
| Q1 24 | 27.4% | 72.6% |
营业利润率FGIRGNX
| Q4 25 | -2.2% | -190.0% | ||
| Q3 25 | 1.0% | -176.3% | ||
| Q2 25 | -2.7% | -296.3% | ||
| Q1 25 | -3.9% | 13.6% | ||
| Q4 24 | -3.5% | -242.1% | ||
| Q3 24 | -0.2% | -256.6% | ||
| Q2 24 | -1.5% | -251.3% | ||
| Q1 24 | -1.0% | -408.8% |
净利率FGIRGNX
| Q4 25 | -8.6% | -221.3% | ||
| Q3 25 | -4.6% | -208.3% | ||
| Q2 25 | -4.0% | -331.8% | ||
| Q1 25 | -1.9% | 6.8% | ||
| Q4 24 | -1.1% | -241.3% | ||
| Q3 24 | -1.5% | -246.3% | ||
| Q2 24 | 0.6% | -237.7% | ||
| Q1 24 | -1.3% | -405.4% |
每股收益（稀释后）FGIRGNX
| Q4 25 | $-1.63 | $-1.30 | ||
| Q3 25 | $-0.86 | $-1.20 | ||
| Q2 25 | $-0.64 | $-1.38 | ||
| Q1 25 | $-0.07 | $0.12 | ||
| Q4 24 | $-0.38 | $-0.99 | ||
| Q3 24 | $-0.29 | $-1.17 | ||
| Q2 24 | $0.08 | $-1.05 | ||
| Q1 24 | $-0.04 | $-1.38 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $1.9M | $230.1M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $17.3M | $102.7M |
| 总资产 | $69.5M | $453.0M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资FGIRGNX
| Q4 25 | $1.9M | $230.1M | ||
| Q3 25 | $1.9M | $274.2M | ||
| Q2 25 | $2.5M | $323.3M | ||
| Q1 25 | $1.2M | $267.9M | ||
| Q4 24 | $4.6M | $234.7M | ||
| Q3 24 | $3.0M | $255.5M | ||
| Q2 24 | $1.3M | $290.4M | ||
| Q1 24 | $3.3M | $338.7M |
股东权益FGIRGNX
| Q4 25 | $17.3M | $102.7M | ||
| Q3 25 | $19.7M | $161.5M | ||
| Q2 25 | $21.3M | $213.7M | ||
| Q1 25 | $21.8M | $274.2M | ||
| Q4 24 | $22.3M | $259.7M | ||
| Q3 24 | $23.5M | $301.4M | ||
| Q2 24 | $23.8M | $348.3M | ||
| Q1 24 | $23.9M | $390.7M |
总资产FGIRGNX
| Q4 25 | $69.5M | $453.0M | ||
| Q3 25 | $73.0M | $525.2M | ||
| Q2 25 | $71.7M | $581.0M | ||
| Q1 25 | $68.5M | $490.9M | ||
| Q4 24 | $75.5M | $466.0M | ||
| Q3 24 | $74.7M | $519.1M | ||
| Q2 24 | $69.9M | $569.4M | ||
| Q1 24 | $68.6M | $629.2M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $2.3M | $-52.3M |
| 自由现金流经营现金流 - 资本支出 | $2.3M | $-52.8M |
| 自由现金流率自由现金流/营收 | 7.5% | -174.0% |
| 资本支出强度资本支出/营收 | 0.2% | 1.7% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-212.5K | $-126.4M |
8季度趋势，按日历期对齐
经营现金流FGIRGNX
| Q4 25 | $2.3M | $-52.3M | ||
| Q3 25 | $-1.9M | $-56.0M | ||
| Q2 25 | $7.6M | $-49.3M | ||
| Q1 25 | $-7.4M | $33.6M | ||
| Q4 24 | $617.4K | $-31.6M | ||
| Q3 24 | $-915.0K | $-40.5M | ||
| Q2 24 | $862.1K | $-45.5M | ||
| Q1 24 | $-8.0M | $-55.5M |
自由现金流FGIRGNX
| Q4 25 | $2.3M | $-52.8M | ||
| Q3 25 | $-2.1M | $-56.5M | ||
| Q2 25 | $7.4M | $-49.7M | ||
| Q1 25 | $-7.7M | $32.6M | ||
| Q4 24 | $-214.1K | $-32.7M | ||
| Q3 24 | $-1.1M | $-40.9M | ||
| Q2 24 | $281.5K | $-46.0M | ||
| Q1 24 | $-8.6M | $-56.0M |
自由现金流率FGIRGNX
| Q4 25 | 7.5% | -174.0% | ||
| Q3 25 | -5.9% | -189.9% | ||
| Q2 25 | 23.8% | -232.8% | ||
| Q1 25 | -23.3% | 36.6% | ||
| Q4 24 | -0.6% | -154.2% | ||
| Q3 24 | -3.0% | -168.9% | ||
| Q2 24 | 1.0% | -206.2% | ||
| Q1 24 | -28.0% | -358.5% |
资本支出强度FGIRGNX
| Q4 25 | 0.2% | 1.7% | ||
| Q3 25 | 0.7% | 1.7% | ||
| Q2 25 | 0.7% | 1.8% | ||
| Q1 25 | 1.1% | 1.2% | ||
| Q4 24 | 2.3% | 5.1% | ||
| Q3 24 | 0.5% | 1.3% | ||
| Q2 24 | 2.0% | 2.1% | ||
| Q1 24 | 2.0% | 3.6% |
现金转化率FGIRGNX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 5.53× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 5.27× | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
FGI
| Sanitaryware | $19.1M | 63% |
| Shower System | $5.8M | 19% |
| Kitchen And Bath Other | $3.3M | 11% |
| Bath Furniture Products | $2.3M | 7% |
RGNX
| Novartis Gene Therapies | $24.2M | 80% |
| Nippon Shinyaku Collaboration And License Agreement | $4.3M | 14% |
| Nippon Shinyaku Services | $1.4M | 5% |
